Glass House Brands announced Today that it is accelerating its 2026 expansion plans, moving ahead with additional greenhouse production and laying the groundwork to sell marijuana and hemp-derived products beyond California as federal reform efforts advance.
The California-based company said it has returned its existing greenhouses to full production capacity after a slowdown earlier in 2025 and ended the year with the most planted acreage in its history. That recovery has prompted the company to speed up previously planned expansion projects, including the buildout of additional greenhouses at its Southern California farm.
Glass House has completed the first phase of Greenhouse 2, its fourth operational greenhouse, with initial production expected to be reflected in first-quarter 2026 results. While the remainder of the greenhouse was originally slated for later in the year, the company now plans full planting by the second quarter of 2026. Once fully operational, Greenhouse 2 is expected to add roughly 300,000 pounds of annual biomass production capacity.
The company has also begun retrofitting Greenhouse 4, which will be used to target international CBD and hemp markets. Glass House said the facility is being positioned to supply future reimbursable CBD programs anticipated under President Donald Trump’s December executive order directing the rescheduling of marijuana.
“We are very pleased with and proud of our team’s ramp back efforts of the past six months for existing greenhouses along with early results from Greenhouse 2 expansion,” said Kyle Kazan, co-founder, chairman and CEO of Glass House. “The Company is ready to put its foot fully back on the gas pedal. We anticipate strong growth in 2026 and beyond.”
Kazan added that the company is preparing for new opportunities tied to rescheduling, including potential cannabis export markets in Europe and elsewhere, where wholesale biomass prices are expected to exceed those in California. Glass House also said it believes it is well positioned to participate in the growth of the U.S. CBD market, citing its existing low-THC strains and ongoing hemp research efforts aimed at pharmaceutical and consumer packaged goods applications.
